Table 3.
Notch receptor and ligand expression levels with respect to clinicopathological features.
| Stratification of HCC | Notch1 | Notch2 | Notch3 | Notch4 | Jagged1 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Studies (Subjects) | OR(95%CI) | P, I 2 | Studies (Subjects) | OR(95%CI) | P, I 2 | Studies (Subjects) | OR(95%CI) | P, I 2 | Studies (Subjects) | OR(95%CI) | P, I 2 | Studies (Subjects) | OR(95%CI) | P, I 2 | |
| Age(year): ≤mean vs >mean | 11(1305) | 1.05(0.71, 1.56) | 0.010, 57.1% | 3(143) | 1.29(0.38, 4.42) | 0.214, 35.0% | 5(517) | 0.89(0.37, 2.09) | 0.031, 62.4% | 4(423) | 0.91(0.36, 2.30) | 0.093, 53.3% | 5(294) | 0.94(0.40, 2.24) | 0.078, 52.4% |
| Gender: Male vs Female | 11(1360) | 1.16(0.96, 1.40) | 0.986, 0.0% | 4(217) | 0.76(0.13, 4.44) | 0.083, 55.1% | 6(612) | 1.10(0.68, 1.78) | 0.756, 0.0% | 4(423) | 1.47(0.87, 2.46) | 0.775, 0.0% | 5(583) | 0.74(0.43, 1.30) | 0.806, 0.0% |
| Tumor size(cm): ≤ 5 vs > 5 | 11(1305) | 0.59(0.41, 0.85)* | 0.001, 65.7% | 3(143) | 0.47(0.15, 1.48) | 0.284, 20.5% | 6(612) | 0.85(0.37, 1.98) | 0.004, 70.6% | 4(423) | 0.89(0.39, 2.00) | 0.138, 45.5% | 6(603) | 1.10(0.73, 1.65) | 0.449, 0.0% |
| Histological grade: Well-moderate vs Poor | 12(1353) | 1.65(0.84, 3.23) | 0.000, 76.3% | 4(199) | 0.68(0.24, 1.89) | 0.642, 0.0% | 6(610) | 0.77(0.50, 1.18) | 0.510, 0.0% | 4(423) | 0.71(0.43, 1.17) | 0.835, 0.0% | 6(604) | 1.51(0.73, 3.12) | 0.077, 49.7% |
| Tumor stage: I-II vs III-IV | 11(1351) | 0.63(0.36, 1.11) | 0.000, 83.9% | 4(217) | 0.39(0.16, 0.96) | 0.473, 0.0% | 6(612) | 0.46(0.20, 1.06) | 0.029, 59.8% | 4(423) | 1.17(0.48, 2.88) | 0.157, 42.4% | 5(452) | 2.24(1.57, 3.20) | 0.365, 7.3% |
| AFP level(ng/mL): ≤mean vs> mean | 9(1165) | 0.95(0.57, 1.58) | 0.001, 68.7% | 2(90) | 1.13(0.45, 2.82) | 0.652, 0.0% | 4(453) | 1.15(0.60, 2.21) | 0.225, 31.1% | 3(359) | 3.24(2.01, 5.21) | 0.367, 0.2% | 5(552) | 1.29(0.53, 3.14) | 0.011, 69.5% |
| Albumin level (g/dL): ≤mean vs > mean | 1(288) | 0.85(0.40, 1.81) | — | — | 1(288) | 1.74(0.75, 4.03) | — | 1(286) | 1.16(0.53,2.55) | — | 1(288) | 0.85(0.40, 1.81) | — | ||
| Etiology: Non-viral vs HBV/HCV | 7(920) | 1.33(0.57, 3.09) | 0.006, 69.2% | 2(98) | 0.69(0.18, 2.63) | 0.194, 40.6% | 4(473) | 1.32(0.76, 2.28) | 0.804, 0.0% | 3(370) | 0.75(0.41, 1.40) | 0.895, 0.0% | 4(533) | 1.34(0.69, 2.61) | 0.841, 0.0% |
| Metastatic: Negative vs Positive | 7(838) | 0.42(0.24, 0.73)* | 0.032, 56.6% | 2(132) | 0.35(0.06, 2.08) | 0.042, 75.7% | 4(414) | 0.58(0.21, 1.64) | 0.042, 68.2% | 2(320) | 2.13(1.27, 3.56) | 0.986, 0.0% | 2(162) | 0.58(0.08, 4.04) | 0.116, 59.5% |
| Multicentric occurrence: Negative vs Positive | 6(786) | 0.80(0.55, 1.18) | 0.382, 5.4% | 1(50) | 1.25(0.27, 5.73) | — | 4(519) | 0.64(0.19, 2.19) | 0.094, 53.1% | 1(288) | 0.37(0.12, 1.16) | — | 2(172) | 1.07(0.40, 2.86) | 0.400, 0.0% |
| Major portal vein invasion: Negative vs Positive | 6(985) | 0.59(0.24, 1.43) | 0.000, 77.4% | 1(50) | 1.32(0.22, 7.87) | — | 4(519) | 0.52(0.20, 1.36) | 0.123, 48.0% | 2(338) | 0.90(0.31, 2.64) | 0.914, 0.0% | 1(50) | 2.47(0.39, 15.73) | — |
| Microvascular invasion: Negative vs Positive | 2(420) | 0.53(0.31, 0.88)* | 0.223, 32.6% | — | 1(288) | 0.66(0.36, 1.18) | — | 1(298) | 1.83(1.14, 2.92) | — | — | ||||
| Liver cirrhosis: Negative vs Positive | 2(422) | 1.03(0.45, 2.38) | 0.044, 75.3% | — | 2(383) | 0.68(0.41, 1.11) | 0.839, 0.0% | 1(288) | 1.00(0.63, 1.60) | — | 1(122) | 0.74(0.31, 1.77) | — | ||
| Capsular invasion: Negative vs Positive | 1(50) | 0.91(0.17, 5.03) | — | 1(50) | 1.40(0.38, 5.20) | — | 2(146) | 1.39(0.58, 3.34) | 0.657, 0.0% | 1(50) | 1.92(0.16,22.61) | — | 2(171) | 0.81(0.40, 1.65) | 0.867, 0.0% |
AFP, α-fetoprotein; HCC, hepatocellular carcinoma; *Result with significant differences.